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The human body is a fascinating arrangement of cellular organization necessary to 
support life; it is also home to trillions of microorganisms.  The largest concentration of these 
commensal microbes exists within the gastrointestinal tract (GI) where bacteria dominate the 
landscape. Accordingly, the vast majority of research performed thus far has been to elucidate 
the role of bacteria; however, commensal fungal species are known to colonize every mucosal 
surface, including the GI of humans.  Moreover, humoral responses to fungal cell walls have 
been shown to be a specific diagnostic marker for Crohn’s disease and not ulcerative colitis.  
However, the role of yeast within the GI both metabolically and immunologically remains largely 
unexplored. For this reason, we set out to investigate how a known commensal yeast species, 
Saccharomyces cerevisiae, and a newly described yeast species in the context of human 
disease, Rhodotorula aurantiaca, influence immune system development and modulate disease. 
Also, given the role of environmental fungi in nutrient cycling on the planet, we were interested in 
how these two species may impact the metabolism of the host.  To address these questions, we 
used two common mouse models of colitis.  In addition, we performed a microarray on colonic 
RNA from germfree mice mono-colonized with our two yeast species and LC/MS on the serum 
of these animals. Here we report that mono-colonization with S. cerevisiae but not R. aurantiaca 
results in a significant increase in products of the purine degradation pathway, including uric 
acid.  Surprisingly, yeast did not induce a robust inflammatory response; however, we observed 
multiple pathways associated with both digestion and epithelial barrier integrity.  We 
demonstrate that animals treated with S. cerevisiae during DSS colitis have worse colonic 
histology, increased serum uric acid levels, and intestinal permeability.  Furthermore, we 
determined that supplementing uric acid alone during DSS colitis recapitulates these effects.  
We postulate that S. cerevisiae alters the colonic histology and intestinal permeability through 
	  
enterocytes and shunted into the purine salvage pathway, resulting in conversion to uric acid 
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Look deep into nature and then you will understand everything better. 
- Albert Einstein
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In recent years, the notion of intestinal health has tantalized American households with 
vigorous marketing campaigns claiming relief from an array of intestinal ailments. Ilya Mechnikov 
first proposed the idea of beneficial intestinal bacteria in his 1907 book, “The Prolongation of 
Life.” And while the concept of beneficial microorganisms is far from a new one, a century later, 
modern-day technologies are beginning to unravel the enormous complexity and vast 
consortium of microorganisms that comprise the mammalian gastrointestinal tract, collectively 























The Microbiota and Their Role in Host Physiology 
The Human gastrointestinal tract (GI) is home to all three domains of life, including a 
substantial virobiome.1-3 Enumerating the amount of microorganisms in this ecosphere can be a 
daunting task. While controversial, it is often noted that the GI contains ten times the amount of 
bacterial cells as cells in the human body4,5. However, these claims are often not cited and 
others have disputed this claim altogether.6,7 Regardless of the exact number of microorganisms 
residing in the GI, it is clear that the number of bacteria, archaea, fungi, and viruses living in and 
on the human body is immense.1,6,7 Bacteria, however, are the dominant kingdom in the GI and 
for this reason have been studied the most extensively. Prokaryotes within the gut perform a 
myriad of useful functions that aid the body in digestion, immune regulation, and even 
behavior.8,9 Specific organisms within the gut contain enzymes that human cells lack; these 
enzymes facilitate the utilization of otherwise undigested carbohydrates.10 Bacteria convert 
complex sugars such as, starches, fiber, and oligosaccharides into short chain fatty acids, such 
as acetic acid, propionic acid, and butyric acid, via a process known as saccharolytic 
fermentation.11 These acids provide energy-rich carbon sources for epithelial cells and assist the 
body in the absorption of dietary minerals like calcium, magnesium, and iron.12  These 
metabolites have also been shown to promote colonic homeostasis by binding to T regulatory 
cells within the gut and promote a regulatory phenotype.13 Multiple studies have demonstrated 
that commensal bacteria can promote both tolerogenic and inflammatory responses; thus, the 
need for an appropriate microbiota is essential for host health. Accordingly, the immune system 
in the GI has a colossal task of discriminating between commensal organisms that provide 
benefit and potential pathogens.11,14  Fungi, however, have been largely ignored in the context of 
their potential benefit to the host. Nonetheless, both the skin and the GI are known to house 
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respectively.15 Recently, several studies have emerged characterizing the mycobiome and what 
impact fungi have on host physiology. However, the contribution both immunologically and 
metabolically that yeast provide the host remains largely unknown.  
 
It’s a Fungal World 
Fungi represent a diverse group of eukaryotic organisms that include yeasts, molds, and 
mushrooms. Fungi have, arguably, had a more positive influence on human health than any 
other microorganism. The budding yeast Saccharomyces cerevisiae, more commonly known as 
bakers yeast, has been used for centuries in rising bread and beer brewing.  Alexander 
Flemming’s discovery that the mold, Penicillium notatum, inhibited colonies of staphylococci in 
1928 would revolutionize the medical community, lead to a Nobel Prize, and was quite possibly 
the most influential discovery of the twentieth century.  Psychotropic compounds, such as 
psilocybin, found in some species of mushrooms have been used in religious ceremonies for 
millennia and have been reported to induce highly spiritual and positive emotions in a blinded 
study using psilocybin naïve volunteers.16  Lastly, humans have suffered the ills of bacteria for 
millennia: Bubonic plague, epidemics of Cholera, scarlet fever, diphtheria, typhoid fever; sexually 
transmitted diseases such as syphilis, gonorrhea, and chlamydia, killed millions before the 
advent of antibiotics and even today remain problematic in the age of antibiotic resistance. While 
several species of fungi have evolved to be infectious in plants, comparatively speaking, few 
fungi are true pathogens in human hosts. Undeniably, the AIDS epidemic of the 1980s created 
the field of medical mycology. Along with advances in transplant technology, chemotherapy, and 
broad-spectrum antibiotics, the significance of fungal opportunists has become far more 
appreciated in the past 30 years. Fungal species such as Candidia albicans, Cryptococcus 
neoformans, Histoplasma capsulatum, Aspergillus flavus, A. fumigatus, Pneumocystis jirovecil, 
and the black mold Stachybotrys chartarum are common opportunistic pathogens seen in 
immunocompromised patients. Unlike bacterial or viral infections, which can be spread from 
person to person, fungal infections are not and are only acquired from the environment or other 
exogenous sources, as was the case in 2012 when injectable steroids became contaminated 
several hundred species of yeast with Malassezia and Candida spp being the most prevalent, 
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with the fungus Exserohilum rostratum.17 The ubiquitous nature of fungi in the environment and 
their ability to be manipulated for human use, along with their consistent presence in human 
hosts and the lack of true pathogens, suggests that the immune system has evolved sufficient 
control and regulatory mechanisms for fungi.  
 
Functional Crosstalk Between the Host and the Microbiota 
The mammalian immune system is classically known for its ability to recognize and clear 
pathogens from the body. However, the vast majority of microorganisms surveyed by the 
immune system are symbionts that live on and in mammalian hosts. In order to permit a complex 
microbial community to live and thrive within the body, the immune system has evolved several 
elegant strategies to compartmentalize these microbes in order to carry out their functions, while 
not mounting metabolically taxing immuno-inflammatory reactions. Both the innate and adaptive 
arms of immunity participate in the modulation of host immunity and are crucial for maintaining 
homeostasis in the GI.18,19  
Pattern recognition receptors (PRR) such as toll-like receptors (TLR) and C-type lectins, 
located on phagocytic as well as intestinal epithelial cells recognize microbe-associated 
molecular patterns (MAMPS). Certain PRR have proven to be important for detection of fungi via 
the binding of sugar moieties in the cell walls of fungi. β-Glucan, for example, comprises at least 
40% of the dry weight of C. albicans; accordingly, mammals have evolved two receptors that 
recognize β-glucan: Dectin-1 and complement receptor 3 (CR3).20  Dectin-1 is a C-type lectin 
originally found on dendritic cells able to provide T cells with co-stimulatory signals; however, 
subsequent research has shown that Dectin-1 is primarily located on myeloid phagocytes where 
it acts to initiate phagocytosis.20 Ligation of Dectin-1 by zymosan has been demonstrated to 
phosphorylate an ITAM-like motif on Dectin-1 and lead to IL-2 and IL-10 production.21 The role of 
CR3 in β-glucan recognition is less defined, though it has been shown that CR3 signals through 
Src/Syk mechanisms and is important for ROS production in neutrophils in response to β-
glucans.20  Mannan, like β-glucan, is another rich carbohydrate in the cell walls of fungi. 
Macrophage mannose receptor (MR) is widely expressed by both macrophages and dendritic 
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cells and has been show to associate with TLR-2 during recognition of Saccharomyces, 
Candida, and Pneumocystis.19,20 Blockade of the MR has been shown to reduce inflammatory 
cytokines; however, little is known regarding mannose receptor signaling. Dectin-2, a C-type 
lectin found on macrophages, has been shown to bind to fungal hyphae, by associating with the 
Fc-R γ-chain leading to TNFα and IL-1ra production.21 While dimorphic yeasts such as C. 
albicans contain mannan in their cell walls and hyphal projections, Dectin-2 preferentially binds 
the latter.21 Consequently, the disparity in cytokine production between Dectin-1 and Dectin-2 
has been proposed to correlate with the clinical outcomes, yeast-dominant infections promoting 
a dampening of the immune response and hyphae-dominant infections resulting in 
inflammation.21 TLR-2 and 4 are key receptors in recognizing multiple pathogenic fungi and are 
highly expressed on phagocytic cells and enterocytes.20,22 However, how these particular 
receptors modulate fungal communities within the GI, given they are likely fully activated by 
bacteria, is not completely understood. Thus, it is clear that antigen-presenting cells can activate 
tolerogenic or immunogenic responses, depending on the antigen presented.23 Furthermore, IgA 
secreted from plasma cells represents an example of adaptive immunity in the gut, as IgA has 
been shown to coat luminal bacteria, although how a humoral response may control fungal 
populations within the lumen has yet to be elucidated.18  
Under homeostatic conditions, these processes allow the host and its microbial 
community to coexist peacefully; however, when these mechanisms break down, an aberrant 
immune response ensues and chronic inflammation develops. Delineating how tolerance to 
intestinal microbiota is maintained and subsequently lost, resulting in chronic inflammation, is of 
particular interest to researchers and clinicians studying and treating chronic inflammatory 
disorders of the bowel.  
 
IBD: A Microbiota-linked Disease 
Inflammatory bowel disease (IBD) is an idiopathic disease comprised of two types of 
chronic intestinal disorders: Crohn’s disease (CD) and ulcerative colitis (UC). IBD affects 
approximately 1.4 million Americans, with most patients being diagnosed between the ages 15 
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to 30 years of age.24 CD is a disease most commonly associated with the ileum of the colon; 
however, it can affect any region of the intestine and is often discontinuous in its presentation.25 
UC primarily affects the rectum but can affect any part of the colon or the whole colon in an 
uninterrupted pattern.25 Advances in sequencing technology have revealed consistent taxonomic 
differences amongst mucosally–associated microbes in CD patients.26 Genome-wide association 
studies have identified several risk alleles associated with the development of IBD; thus, both 
the genotype of the host and the environment can contribute to disease.14,26 As population 
dynamics shift in the GI, either due to genetic deficiencies or exogenous factors such as diet or 
antibiotics, a bloom of organisms that promote inflammation can occur.26,27 This imbalance of 
luminal microbiota is collectively referred to as “dysbiosis”.  One of the most distinguishing 
clinical markers for CD is the presence of antibodies to epitopes within fungal cell walls, 
specifically phosphopeptidomannan28. This humoral response has colloquially been termed: anti-
saccharomyces cerevisiae antibodies (ASCA). However, these complex sugars with chitin 
backbones make up the molecular matrix in multiple phyla of yeast, including Candida and 
Saccharomyces spp, which are both known to colonize the mammalian GI and have been 
shown to contain the epitopes necessary to bind ASCA2,29. ASCA, therefore, are not specific to 
Saccharomyces spp and are most likely induced by Candida spp given Candida’s prevalence in 
the GI2,15. Moreover, patients suffering from CD are heavily colonized with C. albicans; thus, 
fungal overgrowth in the presence of inflammation leads to increased recognition by professional 
antigen presenting cells and a secondary humoral response.15,30 This suggests that fungi play a 
role in the prognosis of IBD. 
 
Colonization: The Major Players 
The vast majority of research regarding dysbiosis of the intestinal microbiota, including 
metabolic and immune functionality, has focused primarily upon its prokaryotic members. Their 
sheer numbers and their potential to be pathogenic qualify them as the predominant kingdom in 
a biome that contributes greatly to host health. Nevertheless, Candida spp. including albicans, 
galbrata, and tropicalis have been shown to dominate the fungal community in multiple mucosal 
	   7	  
sites, including the oral cavity, vagina, and colon of healthy individuals.2,31 The oral cavity has 
even been shown to consist of several genera traditionally thought to be pathogenic, including 
Aspergillius, Fusarium, and Cryptococcus spp.32 It has been known for years that Candidiasis 
can result from antibiotic therapy leading to a disruption of microbial communities and the 
overgrowth of Candida spp.15 However, what influence fungal communities have on bacterial 
populations and vice versa is just now beginning to be appreciated. How do fungal communities 
influence chronic inflammation and how is the dysbiosis of the mycobiome related to disease? 
These are questions investigators have recently started to address; however, the lack of 
standardized protocols, sequencing databases, and bioinformatics approaches will have to be 
resolved in order to overcome the variability seen in different studies thus far.15 
 
A Novel Yeast Identified in Crohn’s Disease Patients 
In an effort to characterize the mycobiome in a cohort of CD patients, Ottman et al. 
evaluated the feces and mucosal milieu for differences in fungal communities. A significant 
difference was observed between mucosally associated and fecal fungi. In addition, fungal 
richness was appreciably higher in CD patients.  Interestingly, the red pigmented, environmental 
Basidiomycete, Rhodotorula aurantiaca, was present in colonic mucosa of 19% of patients with 
UC and 13% of CD patients.31 By contrast, S. cerevisiae was present in the stool of these 
patients, but was not identified in the mucosa. R. aurantiaca is an ubiquitous yeast that has been 
isolated from polar ice caps, soil, air, fruit juices, and indwelling catheters.33 Although not usually 
pathogenic, Rhodotorula species have been reported to cause mycosis in immunocompromised 
patients and have been acknowledged in the GI in other studies.34 In the mid-1980s, cases of 
fungemia due to Rhodotorula spp increased and for the first time, it was recognized as an 
opportunistic pathogen.33  Eight species are associated with the genus Rhodotorula; however, 
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Thesis: How Does the Mycobiome Affect Host Health? 
Due to the differential location of R. aurantiaca and S. cerevisiae in a study of IBD 
patients and the known fungal component for the diagnosis of CD, we set out to explore the 
immunologic and metabolic contribution of R. aurantiaca and S. cerevisiae in the GI. We orally 
gavaged each yeast while employing two different models of chemically induced colitis to study 
how each species modulates inflammation. We hypothesized that due to the appearance of R. 
aurantiaca in the colonic mucosa of CD patients, this would lead to an inflammatory state and 
exacerbate disease. Previous research using Balb/c gnotobiotic mice has shown that upon 
colonization with C. albicans, in the absence of microbiota and functional T cells, animals were 
resistant to extensive mucocutaneous and systemic candidiasis.35 Therefore, given the work 
done previously with yeast and germfree mice and the observation of S. cerevisiae and R. 
aurantiaca in IBD patients, we wanted to know how yeast influence host physiology from a 
transcriptional perspective. Therefore, we mono-colonized germfree mice and took fecal 
samples to evaluate the metabolic capacity individual yeast species confer upon their hosts. As 
the mycobiome represent a minute portion of intestinal contents, we suspected that yeast would 
not influence the metabolic capacity of the germfree mouse significantly; however, we were 
interested if any metabolites in particular could be predicted to influence microbial ecology or 
affect the intestinal mucosa. Accordingly, this masters thesis was to study how fungi, specifically 
yeast, modulate innate and adaptive immune responses, influence the metabolic activity, 













S. cerevisiae Exacerbates Pathology in Two Experimental Models 
 
of Colitis 
Chronic inflammatory disorders such as Crohn’s disease result when tolerogenic 
mechanisms of gut-associated lymphoid tissue (GALT) breakdown, leading to aberrant immune 
responses to innocuous microbes.36 This loss of tolerance leads to decreases in species 
richness and variation among several taxa comprising the mucosal-associated microbiome.26  
Given the humoral response seen in CD patients, and the presence of R. aurantiaca and S. 
cerevisiae being highly represented in the colonic mucosa and stool, respectively, of CD 
patients; we set out to explore how these yeast influence experimental colitis. Using a T-cell- 
driven model of colitis: 2, 4, 6–trinitrobenzene sulfonic acid (TNBS), C57BL/6 mice were orally 
gavaged with 1.0 x 106 CFU of S. cerevisiae or R. aurantiaca daily for 7 days, TNBS colitis was 
induced and followed for 5 days. Disease severity was assessed by percent weight loss and 
histology of the colon. Percent weight loss between treatment groups and control never reached 
significance over three experiments; however, there is a consistent trend of R. aurantiaca 
recovering sooner and more rapidly than S. cerevisiae, which is demonstrated when the average 
weight loss of each cohort over three independent experiments are compared by a students t-
test (Figure 1. A, B). Inflammation of the colon was examined by histology; H&E-stained day 5 
colonic sections of TNBS treated mice, orally gavaged with S. cerevisiae, showed a high degree 
of leukocyte and lymphocyte infiltration into the mucosa, alteration of epithelial structure, and 
near complete crypt loss when compared to untreated controls and mice orally gavaged with R. 
aurantiaca (Figure 1. C). Histological scores were generated from blind scoring of H&E-stained 
colonic tissues (Figure 1. D) In an attempt to explain the altered histology seen in the S. 
cerevisiae cohort, MLNs were processed and stained for the same effector T-cell subsets that 
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were examined previously. Surprisingly, we saw no differences in T-cell subsets, leaving the 
mechanism responsible for the altered histology open to further investigation.  
We next used a model of dextran sodium sulfate (DSS) to explore what effects the 
exogenous addition of yeast has during an experimental model of colitis when barrier function of 
the colonic mucosa is disrupted. C57BL/6 mice were orally gavaged with 1.0x106 CFU of S. 
cerevisiae or R. aurantiaca daily for 7 days; 2.5% (w/v) DSS was then added to the drinking 
water for 8 days. Mice continued to receive daily gavage of live yeast until sacrifice. Here we 
report that animals treated with S. cerevisiae lost more weight by day 7 during DSS colitis 
compared to controls and animals treated with R. aurantiaca (Figure 2. A, B). We also 
demonstrate that animals treated with S. cerevisiae show altered histology compared to DSS 
controls and those treated with R. aurantiaca, recapitulating the effect seen during TNBS colitis  
(Figure 2. C, D). Interestingly, MLNs from animals treated with R. aurantiaca showed a 
significant decrease in the amount of Th17 cells and IL-17 production when compared to DSS 
controls and animals treated with S. cerevisiae (Figure 3. A-D). qRT-PCR performed on RNA 
collected from colons of treated animals confirmed a significant decrease in IL-17F transcripts 
from animals treated with R. aurantiaca  during DSS colitis (Figure 3. E).  
These experiments provide evidence that certain yeast exacerbate disease pathology as 
can be seen when animals are treated with S. cerevisiae in two separate models of experimental 
colitis. Inflammatory T-cell subsets are known to play a role in the pathogenesis of IBD and 
experimental colitis; therefore, in the absence of clear differences, these cell types implies that 
yeast are not inducing a robust inflammatory response, and in the case of R. aurantiaca, are 
even suppressing certain inflammatory T-cell subsets.  
 
Microarray Analysis of Germfree Animals Mono-colonized 
with Commensal Fungi 
Immune system development depends on the presence of an intact microbiota. Indeed, 
germfree mice have deficiencies in multiple aspects of immune system development that can be 
complemented by providing a complex microbial community. Germfree mice provide a tool to 
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understand how a single microbe can dictate immune system development. To understand how 
S. cerevisiae resulted in worse colonic histology in two different models of colitis, as well as how 
yeast, in general, might skew innate and adaptive immune responses in the gastrointestinal 
tract, we took an unbiased approach and looked at gene expression profiles induced by various 
yeast strains in germfree mice. To this end, germfree C57B/6 mice were colonized with, R. 
aurantiaca and S. cerevisie for 6 weeks; RNA was collected from the colon of each animal and 
used for microarray analysis. Colonization with R. aurantiaca and S. cerevisiae revealed 
differential expression in 50 genes and 34 genes, respectively, when compared to germfree 
controls. When both fungal cohorts were analyzed in conjunction and compared to germfree 
animals, 356 genes were significantly different.  Expression analysis between the two fungal 
cohorts revealed 59 genes differentially expressed (Figure 4. A). When performing a pairwise 
comparison of each fungally-associated cohort with germfree controls, the membrane trafficking 
protein Synaptotagmin 10 (Syt10), known to function as a Ca2+ sensor necessary for 
neurotransmitter and hormone release, was the most up- or down-regulated gene, 
demonstrating an 11.5 fold increase in R. aurantiaca mono-association over germfree controls. 
When comparing S. cerevisiae to germfree, a 10.24 increase in Olfactory receptor 1012 
(Olfr1012) was observed and interestingly, Olfr1012 was one of very few genes that were 
differentially expressed between treatment groups (Figure 4. B, C). Olfactory receptors 
constitute the largest multigene family in mammals. Mouse and human genomes have over 
1500 and 900 genes, respectively; here we report that the yeast effects the expression of 34 
olfactory receptors that are significantly different from controls, with three being differentially 
expressed between the two treatment groups (Figure 4. E).37 Also of note was the stress-related 
survival factor, Erythroid differentiation regulator-1 (ERDR1), which has shown to have 
antimetastic effects in melanoma.38 Up-regulation of ERDR1 was present in both mono-
associated cohorts (Figure 4. D).   
Previous studies have shown inflammatory processes as the most common biological 
outcome when germfree mice were mono-colonized with segmented filamentous bacteria (SFB) 
and demonstrate substantial fold increases over control mice.39 As the host immune system 
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expresses a variety of receptors that function to detect yeast, we hypothesized that colonization 
of animals with yeast would also induce a very robust immune response. By comparison, the 
largest fold increase in any gene was only 11.5 fold. Surprisingly, MLNs from mono-colonized 
animals revealed no differences in T-cell subsets. Although several innate programs were 
affected by mono-colonization, we could find no evidence of an adaptive immune response. 
Further corroborating this finding, KEGG pathway analysis revealed that neither inflammation 
nor adaptive immunity was not among the top ten biological processes affected when germfree 
mice were mono-colonized with our two species of yeast. Rather, multiple pathways associated 
with metabolism and digestion were highly influenced by the mono-colonization of yeast (Figure 
5. A-C). Interestingly, pathways relating to tight junction regulation were also among the most 
influenced between the two treatment groups. To further explore this effect, we employed 
Ingenuity, a functional genomic program, to better elucidate the biological relevance of our 
microarray data. Ingenuity analysis confirmed the absence of an inflammatory and adaptive 
immune response and highlighted pathways involved in epithelial adherens and actin 
cytoskeleton signaling (Figure 5. D-F).   
It appears that yeast was treated much more like a food source, rather than a potentially 
infectious agent. Multiple pathways associated with metabolism and cellular adherens, charged 
with regulating the flux of ions or nutrients across a semipermeable membrane, like that of the 
colon, and the dearth of immune effectors, provide evidence for this observation. As barrier 
function was a common denominator in our analysis, it is important to articulate that barrier 
function can be divided into two separate categories: (1) barrier defense and (2) barrier integrity.  
(1) Barrier defense can be defined as the litany of AMPs employed to thwart invading 
pathogens as well as bridle commensal organisms that veer beyond the mucus lining of the GI. 
Global expression analysis revealed a marked increase in antimicrobial peptide (AMPs) 
programs upon mono-colonization, specifically Regenerating islet-derived 3-beta (REG3β) and 
REG3γ (Figure 6. A). AMPs provide an initial line of defense to bacterial, fungal, and viral 
pathogens and have been shown to modulate microbial communities in the gut.18,40 These 
genetic programs were all significantly increased in animals mono-associated with R. aurantiaca, 
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while the same AMPs were only modestly increased in the S. cerevisiae group (Figure 6. B, D). 
Quantitative real-time polymerase chain reaction (qPCR) for REG3β and REG3γ showed an 
insignificant trend in the amplified transcript levels of S. cerevisiae and R. aurantiaca (Figure 6. 
C, E). These data demonstrate that commensal/environmental yeast when mono-colonized in a 
germfree mouse induces a genetic signature aimed at eliminating and/or controlling a diverse 
repertoire of microbes, which is crucial for the maintenance of intestinal barrier defense. 
 (2) Barrier integrity might best be described as the intricate network of transmembrane 
(claudins, occludin) and peripheral membrane  (zonula occludins) proteins that work to control 
the movement of solutes inter- and intracellularly, based on size and charge selectivity.41 
Evaluating the gene expression of these three protein families, we observed no differential gene 
regulation; both yeast seem to induce the same genetic program with R. auarntiaca intensifying 
the concordant effect (Figure 7. A).  In order to delineate the tortuous combination of these 
proteins, we focused specifically on three claudins: 2, 7, and 12 which have been reported to 
enhance barrier function and whose disruption has been associated with IBD; two of which, Cldn 
7 and 12, were significantly reduced in both treatment groups when compared to germfree 
controls (Figure 7. B).41 qRT-PCR from two independent experiments shows no change in 
claudins 7 and 12 transcripts; however, we show that colonization with R. aurantiaca produced a 
significant increase in Claudin 2 expression (Figure 7. C-E). Claudin 2 is a pore forming protein 
necessary for paracellular transport of cations; moreover, claudin 2 expression has been shown 
to regulate colonocyte proliferation and ameliorate DSS colitis, thus providing one explanation as 
to why animals treated with R. aurantiaca suffer less disease than their S. cerevisiae 
counterparts.41,42 Several investigators have begun to evaluate the effect of the microbiota on 
barrier permeability and specifically claudin expression; however, no one has asked how yeast 
may effect the formation of these junctional complexes. Our study provides evidence that yeast 
induce a genetic signature that influences barrier integrity.  
These two modalities, barrier defense and barrier integrity, work together to maintain 
epithelial homeostasis, yet within each modality exists several parameters able to influence its 
function. Genetic predispositions, for example, that augment the microbial composition in the 
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gut, are associated with Intestinal permeability and increase susceptibility to disease.14,26,41 How 
individual members of the microbiota influence barrier function, however, is poorly defined.41 
Conversely, it is well established that the microbiota has a significant impact on host metabolism 
in the gut; moreover, metabolic by-products have been clearly associated with intestinal 
permeability.43 How commensal yeast effect these biological processes remains largely 
unexplored; therefore, we sought to determine if the differences in colonic histology observed 
during chemically induced colitis were a result of host metabolism. 
 
Mono-colonization with S. cerevisiae Leads to Excess 
Purine Degradation Products, Including 
Uric Acid 
Fungi are known inhabitants of the mammalian GI; however, their role in digestion and 
influence upon metabolic pathways has not been established. To investigate the impact fungi 
have on metabolic processes within the colon, we analyzed the feces for 126 metabolites by 
liquid chromatography mass spectrometry (LC-MS) from germfree, mono-colonized (yeast), and 
specific pathogen-free (SPF) animals. Hierarchical clustering analysis reveals a significant 
difference in the fecal metabolic profile (FMP) of germfree and SPF animals (Figure 8. A). To 
further explore the metabolomics of mono-colonized animals, we asked if the mono-colonization 
with yeast results in a FMP that closely resembles that of germfree or SPF mice or an 
intermediate between the two. Moreover, we were interested in the presence of metabolites that 
may result in adverse pathology to the host.  
Principal component analysis (PCA) reveals that indeed mono-colonization with two 
different phyla of yeast produces a FMP that closely resembles that of germfree mice (Figure 8. 
B). However, there was significant variation between mono-colonization and germfree cohorts; 
we observed significant differences in 7.1% (9 out of 126) of fecal metabolites analyzed (Figure 
8. C). Five of the 9: Mannitol, ribitol/xylitol, egosterol, shikamate, and quinic acid, were the most 
significantly different metabolites and the primary drivers of the differences seen between 
germfree and mono-colonized animals (Figure 9. A). Furthermore, these metabolites were also 
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reduced in SPF animals, indicating that commensal fungi may be important for mediating these 
metabolic pathways. In addition to differences seen between mono-association and germfree 
animals, we also observed significant differences between the two treatment groups. Animals 
mono-colonized with S. cerevisiae show a marked increase in hypoxanthine and xanthine over 
both germfree controls and the R. aurantiaca cohort (Figure 9. B). SPF animals, however, had 
nearly 200 fold more of these metabolites (Figure 9. B). We then noticed that uric acid in SPF 
animals was considerably reduced while germ free and mono-colonized animals remained 
elevated (Figure 9. B). Animals colonized with S. cerevisiae remained significantly increased 
over germfree controls (Figure 9. B).  Interestingly, these three metabolites comprise the major 
constituents of the purine degradation pathway (Figure 9. C).44 Although mice metabolize uric 
acid further, higher primates do not and uric acid has been associated with multiple inflammatory 
disorders.45  
These data indicate that, as suspected, bacteria bear the majority of the metabolic 
capacity of the microbiota. Nonetheless, we demonstrate that two different phyla of yeast have 
drastic effects of the FMP with S. cerevisiae, resulting in significantly elevated levels of uric acid. 
How differences in microbial composition influence the production of specific metabolites and 
how those metabolites then affect downstream physiology is an emerging topic of microbiota 
research.46 Uric acid is a potent antioxidant and is correlated with both deleterious and 
ameliorating effects. Our study implies that certain species of yeast may have the ability to 
potentiate uric acid, leading to disrupted barrier function. 
 
Uric Acid Aggravates Disease and Increases  
Intestinal Permeability During DSS Colitis 
The disease phenotype we established, in conjunction with our microarray analysis, 
implied that yeast affects pathways associated with metabolism that can have deleterious effects 
on epithelial integrity.  The metabolomics profile we performed identified three independent 
metabolites existent in the same metabolic pathway; therefore, we asked if uric acid alone could 
recapitulate the effects seen during DSS colitis. To address this, we orally gavaged uric acid at a 
	   16	  
concentration of 10mg/ml during DSS colitis and evaluated the colons for histology as we had 
previously. In addition, we performed a functional assay, using FITC-dextran a model antigen, to 
assess the effect of uric acid on intestinal permeability. And lastly we used a chemiiluminescent 
assay to detect uric acid in the feces and serum from these animals.  
Here we report that treatment with uric acid during DSS colitis results in aggravated 
colonic histology demonstrated by complete destruction of epithelial structure and crypt loss 
(Figure 10. A). Blind scoring of H&E stained colons confirms that uric acid leads to exacerbated 
pathology (Figure 10. B). Remarkably, treatment with uric acid led to increased intestinal 
permeability as measured by FITC flourophores in the serum (Figure 10. C).  As mice contain 
the enzyme uricase, which reduces uric acid, we assayed both the serum and feces of these 
animals to ensure that our delivery system provided substantial uric acid beyond what mice are 
biologically capable of breaking down. We show that uric acid levels were significantly elevated 
in the feces; however, we were not able to show an increase in the serum (Figure 10. D). 
Our previous findings show that particular members of the mycobiome are capable of 
augmenting uric acid levels in the gut; thus, the discovery that uric acid produces adverse 
pathology during experimental colitis and results in increased intestinal permeability is extremely 
exciting. To our knowledge, this is the first time a specific metabolite has been shown to disrupt 
the colonic mucosa and has profound implications for inflammatory disorders of the bowel. 
Several medications known to inhibit purine degradation are currently used to resolve 
inflammatory symptoms in CD.47 These data provide evidence that the microbial composition of 
the gut can indeed worsen an underlying inflammatory condition and in the future may provide 
additional options for therapy in these patients.  
 
Saccharomyces cerevisiae Increases Intestinal Permeability  
and Serum Uric Acid During DSS Colitis 
In order to sufficiently connect the phenotype displayed by S. cerevisiae during DSS 
colitis and the result seen when animals were supplemented with uric acid during DSS colitis, we 
asked if treatment with S. cerevisiae during DSS colitis results in increased serum and fecal uric 
	   17	  
acid levels, and if S.cerevisiae treatment is associated with increased intestinal permeability. 
Therefore, we repeated our DSS experiments using our two model yeasts as before and 
assayed for uric acid in the serum and feces. We also repeated our functional assay for 
intestinal permeability to evaluate if S. cerevisiae could produce the leaky gut phenotype seen 
when animals were given uric acid.  
Here we show that animals orally gavaged with S. cerevisiae during DSS colitis have 
significantly more uric acid in their serum than do DSS controls and animals treated with R. 
aurantiaca (Figure 11. A). No differences were seen in uric acid levels in feces (Figure 11. B). 
Strikingly, animals treated with S. cerevisiae during disease exhibited a significant increase in 
intestinal permeability when compared to DSS controls and animals treated with R. aurantiaca 
(Figure 11. C). Due to the leaky gut phenotype, we wanted to investigate the junctional proteins 
that may be responsible for the observed leaky gut phenotype. qRT-PCR analysis depicted a 
significant increase in Cldn7 when animals were treated with R. aurantiaca (Figure 11. D). Cldn7 
is known to be expressed in the small and large intestine with high variability and, like Cldn2, 
acts as a cation pore for paracellular transport.48 Furthermore, it has been shown to be important 
for E-cadherin regulation and overexpression of Cldn7 was shown to enhance adhesiveness of 
esophageal cells in vitro.48 Our data therefore suggests that members of the mycobiome can 
modulate claudin expression in intestinal epithelial cells through the action of host metabolites.  
Here we provide a mechanistic rationale for the phenotype observed when animals are 
supplemented S. cereivisae during an experimental model of colitis. As many patients with IBD 
are treated with antibiotics as a form of therapy, this can, and has been documented to lead to 
an overgrowth of the mycobiome.15 Furthermore, xanthine oxidase inhibitors such as allopurinol, 
which prevent the formation of uric acid, have shown to improve clinical outcomes in CD 
patients.47 Hence, our study in combination with previous literature, suggests that an increased 
abundance of the mycobiome can lead to metabolic differences within the microenvironment of 
the gut that can negatively affect the intestinal mucosa and prove detrimental to the host. 
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Figure 1. Saccharomyces cerevisiae exacerbates pathology during TNBS colitis. A) 
Average percent weigh loss from three independent experiments. Error bars removed from 
control group for clarity. B) Percent weight loss for each animal from days 2 to 5 were compared 
by a students t-test. Animals treated with S. cerevisiae show reduced ability to recover 
compared to controls and R. aurantiaca-treated animals. C-D) H&E staining of TNBS colons 
shows that animals treated with S.cerevisiae suffered a greater degree of crypt destruction and 
loss epithelial structure than controls and those treated with R. aurantiaca. 
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Figure 2. Saccharomyces cerevisiae recapitulates TNSB phenotype during DSS-induced 
colitis  A) Average percent weight loss from four independent experiments. Asterix denotes a 
significant difference in weight loss in animals treated with S. cerevisiae compared to R. 
aurantiaca. B) Percent weight loss at day 7 from each animal over four independent 
experiments. Animals treated with R. aurantiaca lost significant less weight than those treated 
with S. cerevisiae and trended to loose less than DSS controls. C-D) H&E staining of TNBS 
colons shows that animals treated with S.cerevisiae suffered a greater degree of crypt 
destruction and loss of epithelial structure than controls and those treated with R. aurantiaca. 
 
 



























































DSS + S. cerevisiae































	   20 	  
Figure 3. Treatment with yeast during DSS colitis does not induce robust inflammatory 
response. A) Representative flow plot and quantitative analysis showing reduced CD3+ CD4+ 
IL-17+ positive cells in the mesenteric lymph nodes as well as total Th17 cells (B) and Mean 
fluorescent intensity (MFI) (C) of animals treated with R. aurantiaca during DSS colitis. D) qPCR 
of colonic tissue from DSS animals shows significant reduction in IL-17F transcripts when 
animals were supplemented with R. aurantiaca.  
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Figure 4. Germfree mice mono-colonized with commensal yeast produces transcriptome 
with few differences. A) Venn diagram shows differential gene expression among cohorts. B-D) 
Raw intensity values from the microarray analysis were linearly transformed and compared by a 
students t-test. (B) The Calcium sensor Synaptotagmin 10 generated the differential expression 
between R. aurantiaca and germfree controls. (C) Olfactory receptor 1012 demonstrated the 
greatest differential expression between S. cerevisiae and germfree controls; Olfr1012 was one 
of few genes differentially influenced by the two yeast. (D) Erythroid differentiation regulator-1, 
shown to be important in cell survival is markedly increased during mono-colonization with yeast. 























































































	   22 	  
	  
!
Figure 5. Mono-colonization with commensal yeast influences pathways associated with 
metabolism and barrier function. A) Heat map shows hierarchal clustering of differentially 
regulated genes between mono-associated and germfree animals. B-C) KEGG pathway analysis 
shows the top ten physiological pathways affected by when germfree animals are compared to 
both treatment groups (B) and between the two treatment groups (C). D-F) Ingenuity analysis 
between treatment groups (D), when animals mono-colonized with S. cerevisiae are compared to 
germfree controls (E) and when animals mono-colonized with R. aurantiaca are compared to 
germfree controls (F).  
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Figure 6. Commensal yeast species up-regulate an antimicrobial peptide program upon 
mono-colonization. A) Heat map shows global expression patterns for the regenerating islet 
derived gene family.  B) Raw intensity values of RegIIIβ microarray analysis were linearly 
transformed and compared by a student t-test. C) qRT-PCR performed on colonic tissue from 
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Figure 7. Commensal yeast influence barrier integrity modulating transcripts of junctional 
proteins. A) Heat map shows expression of claudin proteins during mono-colonization. B) Heat 
map shows statistically significant (ANOVA) differences in claudin proteins during mono-
colonization. C-E) qPCR of Cldn expression from colonic tissue. Expression values were 
compared by students t-test. Germfree/R. aurantiaca cohorts: n=8; S. cerevisiae: n=7.  	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Figure 8. Conventional colonization and mono-association with two different yeast 
species biases fecal metabolic profiles. A) Two way hierarchal clustering analysis based on 
colonization status and fecal metabolite abundance. B) Principle component analysis (PCA) of 
fecal metabolite abundance between germfree, SPF, mono-colonization with S. cerevisiae and 
R. aurantiaca. C) PCA of fecal metabolite abundance between germfree and each mono-
colonized cohort. 	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Figure 9. S. cerevisiae influences metabolites in the purine degradation pathway. 
A) Shows fecal abundance of metabolites reduced in SPF and mono-colonized animals. B) 
Shows fecal abundance of metabolites in the purine degradation pathway. C) Purine 
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Figure 10. Addition of uric acid during DSS colitis results in colon pathology and 
increased barrier permeability. A) H&E stained colon sections. B) Histology scores from H&E 
stained colons show worse disease when animals received uric acid during DSS colitis. C) 
Shows fold change of FITC-dextran in the serum. Values were normalized to negative controls 
that received FITC-dextran but not DSS. D) Measurement of uric acid in the feces and serum of 
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Figure 11. S. cerevisiae increases serum uric acid levels and intestinal permeability. A) 
Shows serum uric acid levels. B) Shows fecal uric acid levels. C) Shows fold change of FITC-
dextran in the serum. Values were normalized to negative controls that received FITC-dextran 













































































































































































Despite the fact that environmental fungi live almost exclusively as obligate mutualists, 
we know very little about their functions in the gut or how individual species contribute to host 
health. Here we show that two distinct phyla of yeast differentially influence susceptibility to 
disease by augmenting the metabolic profile in the gut. Specifically, we demonstrate that 
treatment with S. cerevisiae, but not R. aurantiaca, leads to increase abundance of metabolites 
in the purine degradation pathway, including serum levels of uric acid. Moreover, animals treated 
with S. cerevisiae were more susceptible to disease as measured by colonic histology and 
exhibited a higher degree of intestinal permeability, which has been associated with several 
inflammatory disorders of the bowel.49 Additionally, we were able to recapitulate these effects 
when we supplemented uric acid to animals during DSS colitis. Thus, our data imply that some 
yeast have the ability to influence the metabolic capacity of the host, which we show can result 
in metabolites that can further exacerbate disease.  
 
Uric Acid, an Evolutionary Conundrum 
Uric acid is most commonly known and has long been recognized as the etiological 
agent of Gout.50,51 However, uric acid has a long history and has been implicated to both 
ameliorate disease and promote inflammation.50,52 Uric acid is a diprotic acid and a strong 
reducing agent capable of binding Fe3+ and inhibiting lipid peroxidation.52-54 Most animals contain 
the enzyme uricase, which breaks down uric acid to the more soluble compound, allantoin; 
however, during primate evolution, nonsense mutations have made this gene nonfunctional.53 
The lack of uricase in higher primates makes uric acid the final breakdown product in purine 
metabolism.55 Interestingly, the loss of uricase coincides with the inability to synthesize ascorbic 
acid, another powerful reducing agent, which some have proposed as a compensatory 
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mechanism by increasing plasma uric acid levels and thereby reducing potentially damaging 
reactive oxygen species.53  
Gout is an inflammatory disorder of purine catabolism resulting in uric acid crystals, 
known as monosodium urate (MSU), depositing in the joints and periarticular tissues.51 Since 
this discovery over two hundred years ago, the biological significance of uric acid has been 
studied immensely. When cells undergo damage, they release signals known as damage-
associated molecular patterns (DAMPS), alerting the surveying immune system of their 
demise.56 Uric acid has shown to be a DAMP and a powerful adjuvant released during cell injury 
and contributes to the immunostimmulatory effect of surveying immune cells.55,57 Furthermore, it 
has been demonstrated that MSU is capable of up-regulating co-stimulatory molecules on 
dendritic cells and stimulating cytotoxic T lymphocytes (CTLs) in vitro.55  Additional studies have 
reveled that MSU binds to the NALP3 inflammasome resulting in IL-1β and IL-18 production.50 
Macrophages derived from mice, deficient in the molecular constituents of the inflammasome, 
were unable to produce these cytokines when incubated with MSU and exhibited a diminished 
neutrophil influx during a MSU-induced model of peritonitis.50 Hence, uric acid and its derivatives 
have numerous immunomodulatory applications. Forty-five years ago, Edozein et al. 
demonstrated that feeding young males Candida utilis increased both serum and urine uric acid 
levels to levels associated with gout.58 More recently, Hoffman et al. have shown that a diet rich 
in carbohydrates can lead to an increased fugal burden in the GI.3 These data in combination 
with the observation that CD patients have greater abundance of Candida spp. argue heavily 
that factors resulting in a greater abundance of the mycobiome can affect the metabolic outcome 
of the host, which in genetically predisposed individuals can worsen disease.  
The development of radical oxygen and nitrogen species during inflammation has 
proven an effective mechanism for eliminating pathogens. However, during aberrant immune 
responses like that in IBD, these inflammatory mediators can result in tissue damage.59 During 
homeostatic conditions, cells are able to combat these radical species with a host of antioxidant 
defenses, including urate (the ionic form of uric acid).59 Under constant oxidative stress, like that 
seen in chronic inflammation, tissues become depleted of these antioxidant defenses, 
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exacerbating the pathology.59 In a cohort of CD and UC patients, urate, along with several other 
antioxidants, was shown to be significantly reduced in the colonic mucosa of these patients.59 
Another disease of chronic inflammation, Multiple Sclerosis (MS), results from inappropriate 
adaptive immune responses to the central nervous system. Interestingly, serum uric acid levels 
were markedly reduced in a cohort of MS patients and a clear inverse correlation between gout 
and MS was determined by data mining the records of over 20 million patients.52 The nitrogen 
radical, peroxynitite, has been associated with lesions in the brains of MS patients.60 Uric acid, 
however, has been shown to bind and inactivate peroxynitrite.61 Using a chronic model of 
experimental allergic encephalomyelitis (EAE), Hooper et al. demonstrated that therapeutic 
doses of uric acid were capable of inhibiting the onset of clinical disease as well as rescuing 
animals suffering from clinical symptoms.52 Thus, a delicate balance exists between uric acids 
ability to scavenge potentially harmful radical oxygen species and its ability to cause further 
tissue pathology. 
Collectively, these studies provide further evidence to the biological significance of uric 
acid and its potential to be used in medicine. The discovery that MSU is a strong adjuvant and 
potent stimulator of CTLs could one day lead to better vaccine development, as current 
adjuvants are not capable of activating CD8+ T lymphocytes.55 Furthermore, the mutual 
exclusion seen between gout and MS testifies to uric acids’ strong reducing ability and why the 
loss of uricase has contributed greatly to the speciation and health of Homo sapiens.53 Here we 
report that Saccharomyces cerevisiae contributes to increased uric acid levels in the feces of 
mono-associated animals and serum of SPF animals supplemented with S. cerevisiae, 
presumably due to colonocyte injury and subsequent release of urate as an antioxidant defense 
or uptake of fungal metabolites, which are then shunted into the purine salvage pathway (Figure 
12). Further investigation will provide additional insights on yeast and their contribution to 
metabolism. Selecting for a mycobiome that does not result in increased uric acid levels may 
one day prove to reduce the chronicity seen in inflammatory disorders such as gout and IBD.  
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Limitations of Our Study 
One limitation of our study was the lack of a bacterial control in our mono-colonization 
experiment. Though we were able to glean valuable insights into the contribution of fungi both 
immunologically and metabolically from this study, the lack of a mono-colonized animal with a 
commensal bacterium restrained our ability to make comparisons between eukaryotic and 
prokaryotic contributions. Furthermore, due to time and technical constraints we only evaluated 
mesenteric lymph nodes for innate and adaptive immune responses. It is possible that the 
colonic lamina propria will reveal further immune pathology in animals treated with 
Saccharomyces cerevisiae. Furthermore, in our flow cytometry, we did not perform any staining 
for neutrophils; however, these cells have been shown to be important for resistance to mucosal 
invasion from fungi.62  
Although we were able to detect a significant difference in uric acid levels from our 
metabolomics data, these data are difficult to translate to clinical or relevant concentrations of 
uric acid as these values were normalized by weight to conventionally colonized animals. 
Moreover, the metabolomics data were performed on feces and not serum; to date, fecal levels 
of uric acid have not been described to predict or be associated with any disease phenotypes. 
Regardless, the observation that one phyla of yeast contributes to greater cellular insult, 
resulting in worsened colonic histology, increased intestinal permeability and elevated levels of 
serum uric acid implies that individual fungi, despite their low numbers in the gut, impact host 
health from a metabolic perspective. 
 
Future Directions 
These experiments have shed new light on the mycobiome and have opened the door 
for future investigators to pursue multiple avenues regarding fungi and how they contribute to 
host health and the microbial ecology of the gut. In order to completely evaluate how fungi 
contribute to host immune development within the gut, an exhaustive appraisal of immune cells 
including T cells, B cells, dendritic cells, macrophages, and neutrophils from multiple locations 
such as the colonic lamina propria, small intestine lamina propria, mesenteric lymph nodes, and 
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peyers patches should be performed in germfree mice mono-colonized with known commensal 
fungi individually and in combination with restricted flora.  
To assess how the commensal fungal population contributes to disease severity, 
experiments utilizing chemically induced colitis should be executed in animals treated with 
antifungal drugs and evaluated for immune effectors and histology. Establishing the differences 
in disease phenotypes in the absence of a fungal population compared to controls will further 
elucidate how fungi add to chronic disorders of the bowel. Moreover, clear taxonomic differences 
have been demonstrated in patients with CD and UC; however, no one has looked at the 
taxonomic dynamics of fungal ecology during IBD. At a minimum, explication of this will provide 
an additional layer of knowledge to the overall microbial ecology of the microbiota and its 
benefits and detriments to the host.  
Colonization resistance to intestinal pathogens is one of the greatest benefits afforded 
mammalian hosts by the presence of an intact microbiota.22 Several studies have attested to this 
fact, yet, how commensal fungi aid in colonization resistance has not been studied. Are we more 
susceptible to pathogenic organisms in the absence of fungal flora; can particular members of 
the mycobiome protect from intestinal pathogens? These simple yet novel studies will provide 
valuable information about the mycobiome and perhaps even its telos in the human gut.  
Finally, given fungi’s role in nutrient cycling within other complex microbial ecosystems 
like that of soil, their ability to decompose complex plant material that is then utilized by 
symbiotic bacteria within the rhizosphere suggests that their function within the GI may be to 
degrade food particles for use by commensal bacteria.63 Therefore, it is logical to investigate 
how fungi contribute to the metabolic output of the host. Several studies recently have 
highlighted the importance of the microbiota in metabolism and linked individual species with this 
phenomenon; however, not one of them has mentioned, evaluated, or even speculated on the 
fungal flora and their contribution to digestive metabolism.46,64-66 Assaying the metabolic output 
and digestive capability of mice with and without a fungal population will be a first step in 
understanding how fungi aid the host in digestion including the acquisition and consumption of 
nutrients. Our study, evaluating fecal metabolites in animals mono-associated with two different 
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phyla of yeasts, hints at how yeast may influence the abundance of certain metabolites. Given 
our results of elevated uric acid levels, and the phenomenon seen in MS patients as well as 
other diseases, it would be worth investigating if particular elements of the microbiota, perhaps 
yeast, are capable of modulating physiologic levels of uric acid. In addition, what is the clinical 
significance of uric acid in IBD and what effect does it have on intestinal permeability? And what 
is the consequence of uric acid levels in the feces, what are normal levels and how does it get 
there? Determining how components of the microbiota contribute to the generation of 
metabolites, like uric acid, which have both deleterious and beneficial effects will be crucial to 




















Figure 12. Overgrowth of fungal species during IBD leads to increased uric acid 
production and promotes colonic pathology. During homeostatic conditions, an intact 
microbiota, a mucus membrane, and a network of junctional proteins that control the movement 
of solutes across the epithelial barrier preserve epithelial integrity. During chronic inflammation, 
tight junction proteins are disrupted leading to increased permeability, allowing commensal 
organisms and food products to breach the epithelial interface resulting in increased immune 
trafficking, inflammatory cytokines, and humoral responses to an array of bacterial and fungal 
antigens. Antibiotic treatment during IBD can potentiate an overgrowth of fungi and our research 
suggests, that the putative increase in species such as S. cereiviae results in synthesis of uric 
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Microbiota research is as complex as the biological system it intends to study and 
represents a truly interdisciplinary field of science spanning ecology, microbiology, immunology, 
and biochemistry. Understanding, not only the contribution of a given kingdom, but the emergent 
property of the microbiome as a unique symbiotic ecosystem that is mutualisitically inseparable 
from its host, including the ability to manipulate it reproducibly, will be one of the greatest 
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